NO20032006D0 - Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser - Google Patents

Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser

Info

Publication number
NO20032006D0
NO20032006D0 NO20032006A NO20032006A NO20032006D0 NO 20032006 D0 NO20032006 D0 NO 20032006D0 NO 20032006 A NO20032006 A NO 20032006A NO 20032006 A NO20032006 A NO 20032006A NO 20032006 D0 NO20032006 D0 NO 20032006D0
Authority
NO
Norway
Prior art keywords
melagatran
medicament
manufacture
treatment
ischemic disorders
Prior art date
Application number
NO20032006A
Other languages
English (en)
Other versions
NO20032006L (no
Inventor
David Gustafsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20032006D0 publication Critical patent/NO20032006D0/no
Publication of NO20032006L publication Critical patent/NO20032006L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20032006A 2000-11-06 2003-05-05 Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser NO20032006L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/705,912 US6462021B1 (en) 2000-11-06 2000-11-06 Use of low molecular weight thrombin inhibitor
PCT/SE2000/002204 WO2002036157A1 (en) 2000-11-06 2000-11-09 Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders

Publications (2)

Publication Number Publication Date
NO20032006D0 true NO20032006D0 (no) 2003-05-05
NO20032006L NO20032006L (no) 2003-07-01

Family

ID=24835453

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032006A NO20032006L (no) 2000-11-06 2003-05-05 Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser

Country Status (14)

Country Link
US (1) US6462021B1 (no)
EP (1) EP1333855A1 (no)
JP (2) JP2004512376A (no)
KR (1) KR20040004431A (no)
CN (1) CN1455679A (no)
AU (2) AU2001225625B2 (no)
BR (1) BR0017367A (no)
CA (1) CA2428012A1 (no)
IL (1) IL155431A0 (no)
MX (1) MXPA03003980A (no)
NO (1) NO20032006L (no)
NZ (1) NZ525487A (no)
WO (1) WO2002036157A1 (no)
ZA (1) ZA200303013B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
SE0201373D0 (sv) * 2002-05-06 2002-05-06 Astrazeneca Ab Combination therapy
SE0201374D0 (sv) * 2002-05-06 2002-05-06 Astrazeneca Ab Pharmaceutical combination
AU2003263343A1 (en) 2002-09-09 2004-03-29 Trigen Limited Boronic acid salts ant their use in the treatment of thromobis
US7112572B2 (en) 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
GB0306615D0 (en) * 2003-03-22 2003-04-30 Astrazeneca Ab New use
AR061996A1 (es) * 2006-07-17 2008-08-10 Boehringer Ingelheim Int Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE504185C2 (sv) 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
SE9404196D0 (sv) 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE69625230T2 (de) 1995-10-24 2003-09-04 Merck & Co., Inc. Thrombininhibitoren
TW541316B (en) 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602145D0 (sv) 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
SE9603724D0 (sv) 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9704400D0 (sv) 1997-11-28 1997-11-28 Astra Ab Porous inorganic particles as carriers for drug substances
SE9704401D0 (sv) 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.

Also Published As

Publication number Publication date
IL155431A0 (en) 2003-11-23
BR0017367A (pt) 2003-10-07
EP1333855A1 (en) 2003-08-13
ZA200303013B (en) 2004-07-16
NZ525487A (en) 2004-11-26
JP2004512376A (ja) 2004-04-22
MXPA03003980A (es) 2003-08-19
AU2562501A (en) 2002-05-15
JP2005120098A (ja) 2005-05-12
WO2002036157A1 (en) 2002-05-10
CA2428012A1 (en) 2002-05-10
NO20032006L (no) 2003-07-01
US6462021B1 (en) 2002-10-08
AU2001225625B2 (en) 2006-06-15
CN1455679A (zh) 2003-11-12
KR20040004431A (ko) 2004-01-13

Similar Documents

Publication Publication Date Title
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
SE0101932D0 (sv) Pharmaceutical combinations
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
NO20013414D0 (no) Ny anvendelse av melagatran
DE60128100D1 (de) Analgetisches arzneimittel
PT1206444E (pt) Compostos que inibem a actividade da triptase
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
SE0004101D0 (sv) New use
NO20012310D0 (no) Optisk aktiv pyridyl-4H-1,2,4-oksazdiazinderivat og dets anvendelse ved behandling av karsykdommer
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
NO20023111L (no) Utvortes preparat for behandling av pruritus
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
SE0004827D0 (sv) Therapeutic compounds
SE0300535D0 (sv) Treatment of burns
EE200200218A (et) 2-imidasolüül-asendatud karbinoolide kasutamine ravimi valmistamiseks isheemilistest seisunditest tingitud haiguste raviks või profülaktikaks
SE9602262D0 (sv) New use of derivatives of cystine
SE0101762D0 (sv) New use
ITBO990038A0 (it) Pomata per la cura delle lesioni cutanee particolarmente delle ustioni .

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application